The clinical success of anticancer and antiviral vaccines often requires co-administration of an adjuvant, a substance that enhances the immunogenicity of the antigen and potentiates the immune response. However, few adjuvants exhibit sufficient potency and negligible toxicity to be suitable for clinical use; moreover, their mechanisms of action are generally not fully understood. Current subunit vaccines based on weakly immunogenic carbohydrate and glycopeptide antigens are not being very successful in eliciting a strong immune response against cancer, and no such carbohydrate-based anticancer vaccine has yet been approved for humans despite extensive research efforts and several clinical trials. In this context, building upon the PI's previous background and expertise in the area, the research program in the Fernández-Tejada Group has a double, ultimate goal based on applying chemistry to address the above clear gaps in the adjuvant/vaccine field. With this idea in mind, the Chemical Immunology Lab established by Dr. Fernández-Tejada at CIC bioGUNE will develop new improved adjuvants and novel chemical strategies towards more effective, self-adjuvanting synthetic vaccines. Moreover, leveraging the extraordinary facilities and scientific expertise available at CIC bioGUNE, we will also focus on investigating the molecular mechanisms of the synthetic constructs by combining extensive immunological evaluations with molecular target identification studies and detailed conformational analysis. Thus, the Fernández-Tejada Group builds upon a highly multidisciplinary program integrating ambitious objectives and complementary approaches at the chemistry-biology frontier. Research in the Chemical Immunology Lab connects chemical synthesis and chemical/structural biology with cellular and molecular immunology to explore key unresolved mechanistic questions in the adjuvant/vaccine arena with extraordinary chemical precision.
The Fernández-Tejada Lab is funded primarily by the European Research Council through an ERC Starting Grant, which provides €1.5 million funding for a transformative and timely research program aimed at developing novel synthetic self-adjuvanting vaccines with improved properties and efficacy, as well as unraveling the molecular basis and three-dimensional structure underlying the biological activity of these constructs.
-
Group Leader
Alberto Fernández-Tejada
Ikerbasque Research Professor POSTDOCTORAL RESEARCHER -
Vikram Basava
-
Abhijit Saha
TECHNICIANS / DOCTORAL CANDIDATES -
Alba Mosteiro Couso
-
Alex Sierra Marrero
-
Mirelys Sáenz
Members
Latest Publications
Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen
Pifferi, C; Aguinagalde, L; Ruiz-de-Angulo, A; Sacristán, N; Baschirotto, PT; Poveda, A; Jiménez-Barbero, J; Anguita, J; Fernández-Tejada, A;
CHEMICAL SCIENCE
2023-03-01
Chemical biology tools to interrogate the roles of O-GlcNAc in immunity
Saha, A; Fernández-Tejada, A;
FRONTIERS IN IMMUNOLOGY
2023-01-26
Novel Oxime-Derivatized Synthetic Triterpene Glycosides as Potent Saponin Vaccine Adjuvants
Fuentes, R; Aguinagalde, L; Pifferi, C; Plata, A; Sacristan, N; Castellana, D; Anguita, J; Fernandez-Tejada, A;
FRONTIERS IN IMMUNOLOGY
2022-05-06
Design, synthesis, and initial immunological evaluation of glycoconjugates based on saponin adjuvants and the Tn antigen
Fuentes, R; Aguinagalde, L; Sacristán, N; Fernández-Tejada, A;
CHEMICAL COMMUNICATIONS
2021-10-14
Advances in chemical probing of protein O-GlcNAc glycosylation: structural role and molecular mechanisms
Saha, A; Bello, D; Fernández-Tejada, A;
CHEMICAL SOCIETY REVIEWS
2021-08-02
Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation
Schijns, V; Majhen, D; van der Ley, P; Thakur, A; Summerfield, A; Berisio, R; Nativi, C; Fernández-Tejada, A; Alvarez-Dominguez, C; Gizurarson, S; Zamyatina, A; Molinaro, A; Rosano, C; Jakopin, ...
PHARMACEUTICS
2021-04-01
Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action.
Pifferi, Carlo; Fuentes, Roberto; Fernandez-Tejada, Alberto;
Nature Reviews Chemistry
2021-03-01
Replacing the Rhamnose-Xylose Moiety of QS-21 with Simpler Terminal Disaccharide Units Attenuates Adjuvant Activity in Truncated Saponin Variants
Fuentes, R; Ruiz-de-Angulo, A; Sacristán, N; Navo, CD; Jiménez-Osés, G; Anguita, J; Fernández-Tejada, A;
CHEMISTRY-A EUROPEAN JOURNAL
2021-02-04
Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action.
Pifferi, Carlo; Fuentes, Roberto; Fernandez-Tejada, Alberto;
Nature reviews. Chemistry
2021-01-25
Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action
Pifferi, C; Fuentes, R; Fernández-Tejada, A;
NATURE REVIEWS CHEMISTRY
2021-01-25
Synthetic carbohydrate-based HIV-1 vaccines.
Bastida, Inaki; Fernandez-Tejada, Alberto;
Drug discovery today. Technologies
2020-12-01
Therapeutic Pretargeting with Gold Nanoparticles as Drug Candidates for Boron Neutron Capture Therapy
Feiner, IVJ; Pulagam, KR; Gómez-Vallejo, V; Zamacola, K; Baz, Z; Caffarel, MM; Lawrie, CH; Ruiz-de-Angulo, A; Carril, M; Llop, J;
PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION
2020-09-23
Modulation of immune responses using adjuvants to facilitate therapeutic vaccination
Schijns, V; Fernández-Tejada, A; Barjaktarovic, Z; Bouzalas, I; Brimnes, J; Chernysh, S; Gizurarson, S; Gursel, I; Jakopin, Z; Lawrenz, M; Nativi, C; Paul, S; Pedersen, GK; Rosano, C; Ruiz-de-Angulo, ...
IMMUNOLOGICAL REVIEWS
2020-06-28
Chemical synthesis and immunological evaluation of new generation multivalent anticancer vaccines based on a Tn antigen analogue
Pifferi, C; Ruiz-de-Angulo, A; Goyard, D; Tiertant, C; Sacristán, N; Barriales, D; Berthet, N; Anguita, J; Renaudet, O; Fernández-Tejada, A;
CHEMICAL SCIENCE
2020-05-07
Exploiting structure-activity relationships of QS-21 in the design and synthesis of streamlined saponin vaccine adjuvants
Ghirardello, M; Ruiz-de-Angulo, A; Sacristan, N; Barriales, D; Jiménez-Barbero, J; Poveda, A; Corzana, F; Anguita, J; Fernández-Tejada, A;
CHEMICAL COMMUNICATIONS
2020-01-16
β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine
Wang, HX; Yang, B; Wang, YL; Liu, F; Fernández-Tejada, A; Dong, SW;
CHEMICAL COMMUNICATIONS
2019-01-07
Design, synthesis and evaluation of optimized saponin variants derived from the vaccine adjuvant QS-21
Fernández-Tejada, A;
PURE AND APPLIED CHEMISTRY
2017-09-01
Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth
Rao, TD; Fernández-Tejada, A; Axelrod, A; Rosales, N; Yan, XJ; Thapi, S; Wang, A; Park, KJ; Nemieboka, B; Xiang, JY; Lewis, JS; Olvera, N; Levine, DA; Danishefsky, SJ; Spriggs, DR;
ACS CHEMICAL BIOLOGY
2017-08-01
Quillaja saponin variants with central glycosidic linkage modifications exhibit distinct conformations and adjuvant activities
Walkowicz, WE; Fernández-Tejada, A; George, C; Corzana, F; Jiménez-Barbero, J; Ragupathi, G; Tan, DS; Gin, DY;
CHEMICAL SCIENCE
2016-01-01
Glycans in Medicinal Chemistry: An Underexploited Resource
Fernández-Tejada, A; Cañada, FJ; Jiménez-Barbero, J;
CHEMMEDCHEM
2015-08-01